The potent anti-tuberculosis activity and long half-life of bedaquiline make it an attractive 20 candidate for long-acting/extended release formulations for treatment of latent tuberculosis 21 infection (LTBI). Our objective was to evaluate a long-acting injectable (LAI) bedaquiline 22 formulation in a validated paucibacillary mouse model of LTBI. Following immunization with 23
INTRODUCTION 39
The crux of global efforts to eliminate tuberculosis (TB) is the prevention of Mycobacterium 40 tuberculosis transmission in the population. With approximately 10 million incident cases of TB 41 occurring annually (1) , the identification and treatment of individuals with active disease is 42 clearly necessary for interrupting transmission. Addressing incident TB in the population, 43 however, will not be sufficient to end the global epidemic, as the World Health Organization 44
(WHO) has stated that up to one-third of the world's population may be latently infected with M. 45 tuberculosis, referred to as latent TB infection (LTBI) (2). This reservoir of potentially billions of 46 people serves as an ever-present source of new TB cases, independent of recent transmission 47 events (3). Thus, the identification and treatment of individuals with LTBI is also an essential 48 component of the WHO's End TB Strategy (2, 4). 49
50
There are currently four WHO-recommended LTBI treatment regimens: daily isoniazid 51 monotherapy for 6-9 months, daily rifampin for 3-4 months, daily rifampin plus isoniazid for three 52 months, and weekly rifapentine plus isoniazid for three months (2). When completed, all four 53 regimens are highly and equivalently efficacious in reducing the risk of developing active TB 54 disease, but the shorter (i.e., 3-4 month) regimens are associated with higher rates of 55 completion than the longer (i.e., 6-9 month) regimen (5-7). However, ensuring treatment 56 completion of the three-or four-month regimens is still a formidable challenge for TB control 57 programs. The availability of efficacious regimens even shorter than three months could further 58 improve treatment completion rates. An example is the 1-month daily rifapentine plus isoniazid 59 regimen recently evaluated in a phase 3 clinical trial for the treatment of LTBI in individuals 60 infected with HIV (8) ; the efficacy of this regimen was not inferior to the 9-month control regimen 61 of daily isoniazid and was associated with statistically significantly higher rates of treatment 62 completion. 63 64 7 treatment, only the B 2.67 (5/7) regimen was significantly less bactericidal than the R 10 (5/7) 143 control (p < 0.0001). For mice that received one or two injections of B LAI-160 (1/28), lung CFU 144 counts were equivalent to those in mice that received the same total bedaquiline dose 145 administered as a daily oral regimen, B 8 (5/7) for 4 or 8 weeks, respectively (p > 0.05). The lung 146 CFU counts in mice that received a single injection of B LAI-160 declined between each time point 147 ( Figure S1C) . After 12 weeks of treatment, their CFU counts were lower than those observed in 148 mice that received the same total dose of bedaquiline (160 mg/kg) via daily oral dosing with B 2.67 149 (5/7) (p = 0.0002), with the former regimen resulting in a decline of about 3 log 10 CFU/lung and 150 the latter resulting in a decline of 1.7 log 10 CFU/lung, compared to untreated control mice 151 (Figure S1D). In mice that received a total bedaquiline dose of 320 mg/kg, either through two 152 injections of B LAI-160 or through daily oral dosing of B 5.33 (5/7), the decline in lung CFU counts 153 was similar at about 3 log 10 CFU/lung (p > 0.05) ( Figure S1E ). For mice that received a total 154 bedaquiline dose of 480 mg/kg via three injections of B LAI-160 (1/28), the lung CFU counts were 155 modestly higher than in mice that received the equivalent total dose through daily oral dosing 156 with B 8 (5/7) (Figure S1F), and the difference was not statistically significant. 157
158

DISCUSSION 159
Although highly efficacious regimens exist for the treatment of LTBI, low treatment completion 160 rates hinder their practical effectiveness (2, 6, 7, 36). The use of LAI drug formulations for LTBI 161 treatment could simplify treatment and improve completion rates (9). It may also overcome 162 limitations of poor or variable oral bioavailability, mitigate concentration-dependent toxicity and 163 drug-drug interactions, and ease administration in children. A bedaquiline LAI-based LTBI 164 regimen could confer these benefits to contacts of MDR-TB patients, for whom short-course 165 rifamycin-containing regimens are likely to be ineffective as preventive therapy. Here, we report 166 the development and initial evaluation of an LAI formulation of bedaquiline with a promising PK 167 and pharmacodynamic profile for use in LTBI treatment. While the bacterial burden associated with human LTBI is unknown, it is considered to be less 170 than 4 log 10 CFU, as the lower limit of detection with acid-fast smears is approximately 4 log 10 171 CFU/mL sputum (37-39). Although mice are often not considered to develop latent infection with 172 M. tuberculosis, the model used in this study produces a stable, chronic paucibacillary lung 173 infection that is ≤4 log 10 CFU/lung (32-34, 40). Thus, this model can be used to evaluate the 174 activity of drugs and regimens against an overall non-replicating M. tuberculosis population 175
representing the presumed upper limit of infection in human LTBI. Moreover, this model has 176 been validated through a number of experiments demonstrating the equivalent efficacy of the 177 three rifamycin-based LTBI regimens currently recommended by the WHO (32-34, 41), as well 178 as the 1-month daily isoniazid-rifapentine regimen recently evaluated in a phase 3 clinical trial 179 (8) . Furthermore, the superiority of these rifamycin-based regimens to six months of isoniazid in 180 this model is consistent with the results of a meta-analysis of clinical trials suggesting that 181 rifamycin-based regimens may have superior efficacy (42) . Thus, experimental and clinical 182 evidence supports the use of this model for the preclinical evaluation of LTBI treatment 183
regimens. 184 185
In the present experiment, our M. tuberculosis challenge infection resulted in a larger infectious 186 dose than expected. Our goal was to implant approximately 1.0-1.5 log 10 CFU/lung (32-34), but 187 our actual implantation was slightly more than 2 log 10 CFU/lung. As a result, the M. tuberculosis 188 lung burden was somewhat higher than intended at the start of treatment (Day 0), averaging 189 4.75 log 10 CFU (Table 3) . Nevertheless, the M. tuberculosis lung burden remained stable in 190 untreated control mice throughout the duration of the experiment, indicating that the model was 191 still suitable for the evaluation of LTBI regimens. Indeed, the bactericidal activity of the R 10 (5/7), 192 H 50 P 15 (1/7), and B 25 (5/7) control regimens, which resulted in decreases of 3, 4.5, and 4.9 log 10 193 CFU/lung, respectively, after 12 weeks of treatment, was of the same magnitude as that 194 9 observed in previous studies (32-34). Thus, the higher implantation and Day 0 CFU counts did 195 not affect the relative activity of the drugs against this stable bacterial population in the mouse 196 lungs. 197
198
One of the most striking findings from this study was the apparent duration of bactericidal 199 activity associated with a single dose of the long-acting bedaquiline formulation. One injection of was about twice as long as the usual incubation period but was necessitated by a delay in the 311 availability of the LAI formulation. Five mice were sacrificed on Day 0 to determine pretreatment 312 bacterial lung levels as previously described (34) and as outlined in Table S3 . Mice were 313 randomized into one of the ten treatment regimens described in Table 2 . Doses of rifampin, 314 isoniazid, and rifapentine were chosen to achieve similar plasma exposures (based on area 315 under the plasma concentration-time curve) in mice as are achieved with recommended human 316 doses for treatment of LTBI (49, 50). The daily bedaquiline dose of 25 mg/kg represents the 317 standard dose used in TB treatment studies in mice (22, 28). The daily oral bedaquiline doses of 318 2.67, 5.33, and 8 mg/kg were chosen to administer the same total amount of bedaquiline over a 319 12-week period as one, two, and three doses, respectively, of the LAI bedaquiline formulation, 320
which was administered at 160 mg/kg per dose. For drugs administered by gavage (all drugs 321 except for the long-acting bedaquiline formulation), drug solutions were prepared to deliver the 322 desired dose based on an average mouse body mass of 20 g in a volume of 0.2 mL; drug 323 solutions were prepared weekly and stored at 4 °C. Rifampin and isoniazid were purchased 324 14 from Millipore-Sigma and prepared in distilled water; rifapentine (Priftin ® ) tablets were 325 purchased from a local pharmacy and prepared in distilled water. Orally-administered 326 bedaquiline was dissolved in 20% (w/v) 2-hydroxypropyl-β-cyclodextrin adjusted to pH ~2 with 327 1N HCl. The LAI bedaquiline formulation was stored at 4 °C. The 160 mg/kg dose (based on an 328 average mouse body mass of 20 g) was administered by two intramuscular injections (8 µL 329 each, one into each hind thigh) using a BD Veo TM insulin syringe with BD Ultra-Fine TM 3/10 mL 6 330 mm × 31 G needle with half-unit scale. Treatment was administered for up to 12 weeks, with 331 five mice per treatment group sacrificed 4, 8, and 12 weeks after Day 0. At sacrifice, lungs were 332 removed and homogenized, and CFU counts were determined as previously described (34) 
